RT Journal Article SR Electronic T1 Selective IgA2 deficiency in a patient with small intestinal Crohn’s disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.12.03.22282315 DO 10.1101/2022.12.03.22282315 A1 Canales-Herrerias, Pablo A1 Garcia-Carmona, Yolanda A1 Meringer, Hadar A1 Martinez-Delgado, Gustavo A1 Tankelevich, Michael A1 Colombel, Jean-Frederic A1 Cunningham-Rundles, Charlotte A1 Cerutti, Andrea A1 Mehandru, Saurabh YR 2022 UL http://medrxiv.org/content/early/2022/12/07/2022.12.03.22282315.abstract AB The human IgA response is composed of two structurally different subclasses termed IgA1 and IgA2. Compared to IgA1, IgA2 has a shorter hinge region, which makes it more resistant to bacterial proteases. IgA1 is produced both systemically and in mucosal surfaces, whereas IgA2 is mostly confined to the intestines. While the overall IgA response is known to be involved in intestinal homeostasis, the specific contribution of IgA1 and IgA2 remains largely unknown (Chen 2020). Selective IgA deficiency (SIgAD) is the most prevalent primary immune deficiency. About half of SIgAD cases are associated with heterogeneous but generally mild clinical manifestations. Anecdotal evidence of IgA2 deficiency is available (van Loghem 1983, Ozawa 1986, Engström 1990), however no associations with clinical manifestations have been reported.Here, we describe the occurrence of a selective IgA2 deficiency in a patient (CD068) with small intestinal Crohn’s disease (CD). The patient had undetectable IgA2+ cells and secreted IgA2 antibody in both intestine and circulation. Among other features, patient CD068 presented with duodenal and ileal inflammation. To our knowledge, this is the first case of IgA2 deficiency with a potential link to IBD, which might shed new insights into potential IgA2-specific functions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the following grants: Anonymous Donor (SM and JFC), NIH/NIDDK R01 123749 (SM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of the Icahn School of Medicine at Mount Sinai (17-01304).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors